Susquehanna Maintains Neutral on Snap, Lowers Price Target to $14

Susquehanna analyst Shyam Patil maintains Snap (NYSE:SNAP) with a Neutral and lowers the price target from $34 to $14.

byBenzinga Newsdesk

May 25, 2022

1 minute read

Susquehanna analyst Shyam Patil maintains Snap (NYSE:SNAP) with a Neutral and lowers the price target from $34 to $14.

How Novavax Stock Looks Headed Into Q1 Earnings

By Melanie Schaffer

Today, 10:13 PM

Novavax, Inc. (NASDAQ: NVAX) is set to print its first-quarter financial results after the market close on Thursday. The stock was trading more than 6% lower, at one point, heading into the event.

NVAX

Berkshire Hills Bancorp Q2 EPS $0.44 Beats $0.29 Estimate, Sales $75.39M Beat $73.45M Estimate

By Benzinga Newsdesk

Today, 10:13 PM

Berkshire Hills Bancorp (NYSE:BHLB) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.29 by 51.72 percent. This is a 438.46 percent increase over losses of $(0.13) per share

BHLB

FDA
News

Apellis Pharma Reports Exclusive Research Collab With Beam Therapeutics To Apply Base Editing To Discover Novel Therapies For Complement-Driven Diseases

By Benzinga Newsdesk

Today, 10:13 PM

Collaboration combines Apellis’ expertise in complement, a complex biological system, with Beam’s proprietary base editing platform Companies will collaborate on six research programs directed to tissues

APLS

Media
News

Nio Has Not Completely Halted Production As Widely Believed: Report

By Rachit Vats

Today, 10:13 PM

Nio Inc’s (NYSE: NIO) production lines are partially running over weekdays and completely halted only on weekends due to supply snarls, CnEVpost reported on Wednesday.&nbs

NIO

Susquehanna Maintains Neutral on Snap, Lowers Price Target to $14

Related Posts

How Novavax Stock Looks Headed Into Q1 Earnings

Berkshire Hills Bancorp Q2 EPS $0.44 Beats $0.29 Estimate, Sales $75.39M Beat $73.45M Estimate

Apellis Pharma Reports Exclusive Research Collab With Beam Therapeutics To Apply Base Editing To Discover Novel Therapies For Complement-Driven Diseases

Nio Has Not Completely Halted Production As Widely Believed: Report